Programma

Coffee break

Tijd: 10:45 - 11:30 CET

✕

Antibody Drug Conjugates

Tijd: 15:55 - 16:20 CET

Jordi Remon

✕

KRAS mutated NSCLC

Tijd: 15:30 - 15:55 CET

Alessandra Curioni, University and Hospital Fribourg

✕

1st line in EGFR+ NSCLC

Tijd: 14:40 - 15:05 CET

Joop de Langen

✕

New combination treatments from a regulatory perspective

Tijd: 14:15 - 14:40 CET

Sahar Waalwijk van Doorn - Khosrovani

✕

Lung Cancer from an evolutionary perspective: therapeutic consequences. TRACERx study

Tijd: 13:45 - 14:15 CET

Nicolas McGranahan

✕

Vera Bonta Award 2026

Tijd: 13:30 - 13:45 CET

✕

Screening without losing; use of risk models in Lung Cancer Screening

Tijd: 11:55 - 12:20 CET

Oluf Dimitri Røe, Norwegian University of Science and Technology

✕

Are biomarkers a useful tool for early detection of lung cancer?

Tijd: 11:30 - 11:55 CET

Luis Seijo, Clínica Universidad De Navarra

✕

Optimizing radiotherapy in combination treatment for SCLC

Tijd: 10:20 - 10:45 CET

Bjørn Henning Grønberg, Norwegian University Of Science And Technology

✕

New drugs, new side effects: Cytokine Release Syndrome and other toxicities

Tijd: 09:55 - 10:20 CET

Anne-Marie Dingemans, Erasmus MC

✕

Finally: New treatment options for SCLC

Tijd: 09:30 - 09:55 CET

Martin Schuler

✕

Welcome

Tijd: 09:25 - 09:26 CET

Sjaak Burgers

✕

Drinks

Tijd: 16:20 - 17:00 CET

✕

Who can we spare immunotherapy? Biomarkers

Tijd: 16:00 - 16:05 CET

Prof. dr. Alessandra Curioni, University Freiburg, Switzerland

✕

Targeted treatment in early stage NSCLC

Tijd: 15:00 - 15:05 CET

Dr. Suresh Ramalingan, Emory University, United States

✕

First line options for EGFR+ NSCLC

Tijd: 14:30 - 14:35 CET

Prof. dr. David Planchard, Thoracic oncologist, Gustave Roussy

✕

Lunch

Tijd: 12:20 - 13:30 CET

✕

What to do with all these data?

Tijd: 10:50 - 10:55 CET

Dr. J.A. de Langen

✕

Immunotherapy and comorbidities, the side effect treatment beyond steroids

Tijd: 15:30 - 15:35 CET

Prof. Jarushka Naidoo, Medical Oncologist, Beaumont Hospital And RCSI University

✕

”Are you NUTs”? Diagnostical and molecular challenges in squamous cell lung cancer

Tijd: 12:10 - 12:15 CET

Dr. Gerrina Ruiter, Longarts, AVL

✕

Vaping: A lifeline for ‘chain smokers’ or a ‘Trojan horse’? And what is our responsibility?

Tijd: 14:00 - 14:05 CET

Frank Borm, Longarts, LUMC

✕

Coffee break

Tijd: 15:05 - 15:30 CET

✕

Surgery is key in the treatment of stage III NSCLC. 

Tijd: 10:25 - 10:26 CET

Prof. Eric Lim, Brompton, London

✕

Radiotherapy is key in the treatment of stage III NSCLC

Tijd: 10:00 - 10:05 CET

Prof. Dr. Med. Matthias Guckenberger, University Hospital, Zurich

✕

Neo-adjuvant therapy: lessons from other malignancies (than NSCLC)

Tijd: 11:40 - 11:45 CET

Dr. Myrjam Chalabi, Internist-oncoloog, NKI-AVL

✕

The Legend of the RECIST criteria: Will Artificial Intelligence Take Over Tumor Measurement?

Tijd: 09:30 - 09:35 CET

Dr. Kevin Groot Lipman, NKI-AVL

Illaa Smesseim, longarts en arts-onderzoeker, NKI-AVL

✕

Registration

Tijd: 09:00 - 09:30 CET

✕